Transgenomic to Present at the Lazard Capital Markets 9th Annual Healthcare Conference

Before you go, we thought you'd like these...
Before you go close icon

Transgenomic to Present at the Lazard Capital Markets 9th Annual Healthcare Conference

OMAHA, Neb.--(BUSINESS WIRE)-- Transgenomic, Inc. (OTCBB: TBIO) today announced that Craig Tuttle, Chief Executive Officer of Transgenomic, will be presenting at the Lazard Capital Markets 9th Annual Healthcare Conference on Wednesday, November 14, 2012 at 1:30 PM Eastern Time in New York City.

The presentation will be webcast live at http://wsw.com/webcast/lz13/tbio/and is available for viewing at the Company's web site at http://www.transgenomic.com/events.asp?id=6, where it will be archived for 90 days.


About Transgenomic

Transgenomic, Inc. (www.transgenomic.com) is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. The Company is a global leader in cardiac genetic testing with a family of innovative products, including its C-GAAP test, designed to detect gene mutations which indicate cardiac disorders, or which can lead to serious adverse events. Transgenomic has three complementary business divisions: Transgenomic Clinical Laboratories, which specializes in molecular diagnostics for cardiology, oncology, neurology, and mitochondrial disorders; Transgenomic Pharmacogenomic Services, a contract research laboratory that specializes in supporting all phases of pre-clinical and clinical trials for oncology drugs in development; and Transgenomic Diagnostic Tools, which produces equipment, reagents, and other consumables that empower clinical and research applications in molecular testing and cytogenetics. Transgenomic believes there is significant opportunity for continued growth across all three businesses by leveraging their synergistic capabilities, technologies, and expertise. The Company actively develops and acquires new technology and other intellectual property that strengthens its leadership in personalized medicine.



Investor Contact
Argot Partners
David Pitts, 212-600-1902
david@argotpartners.com
or
Company Contact
Transgenomic, Inc.
Investor Relations, 402-452-5416
investorrelations@transgenomic.com

KEYWORDS:   United States  North America  Nebraska

INDUSTRY KEYWORDS:

The article Transgenomic to Present at the Lazard Capital Markets 9th Annual Healthcare Conference originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners